Table 3.
Association of Clinical Parameters with IOP Reduction in Omani Eyes
| IOP Reduction | n | Mean±SD | p-value |
|---|---|---|---|
| PXG group | |||
| PXG | 21 | 19.57±4.35 | 0.302a |
| Non-PXG | 78 | 21.01±5.91 | |
| Use of PGA | |||
| Yes | 36 | 21.14±6.66 | 0.562a |
| No | 63 | 20.45±4.99 | |
| Medication use | |||
| Yes | 54 | 21.02±5.99 | 0.543a |
| No | 45 | 20.32±5.21 | |
| Baseline IOP | |||
| ≤21 | 12 | 15.42±3.09 | <0.001a |
| >21 | 87 | 21.43±5.52 | |
| Glaucoma subtype | |||
| POAG | 42 | 18.69±5.87 | <0.001b |
| PXG | 21 | 19.57±4.35 | |
| OHTN | 18 | 25.22±4.83 | |
| MMG | 18 | 22.19±4.30 | |
| Correlation value (r) | |||
| HVF MD | 0.079 | 0.443c | |
| Total energy | 0.078 | 0.444c | |
| Energy per shot | −0.125 | 0.217c | |
| CCT | 0.289 | 0.004c | |
| Refraction | 0.092 | 0.366c | |
Notes: aMann–Whitney test; bKruskal–Wallis test; cPearson correlation test.